Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRLS - Chrysalis : Any followers ? Any comments ? -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (30)	11/13/1997 6:22:00 PM
From: BulbaMan	Read Replies (1) \| Respond to of 51

Unlike GZTC, CRLS is not really a pure play on transgenics. And I imagine the stock price of CRLS will be driven by the performance of its contract research business. Since I think there'll be increasing amounts of money spent on research by biotechs and pharmaceuticals, I expect CRLS's revenues and earnings (and stock price) to grow nicely. In my mind, CRLS's transgenics-related patents are an extra bonus for shareholders. CRLS is a very small company. And, assuming sales of transgenic animals/plants really begin to grow, my impression is that CRLS's royalties could become quite significant for their bottom line. I doubt anyone can predict the extent of such royalties, but given CRLS's super-cheap stock price it seems you're getting the transgenics bet for free.